- Home
- OP vs PRPO Comparison
OP vs PRPO Comparison
Compare OP & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OP
- PRPO
- Stock Information
- Founded
- OP 2021
- PRPO N/A
- Country
- OP Greece
- PRPO United States
- Employees
- OP N/A
- PRPO N/A
- Industry
- OP
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- OP
- PRPO Industrials
- Exchange
- OP Nasdaq
- PRPO Nasdaq
- Market Cap
- OP 9.5M
- PRPO 17.1M
- IPO Year
- OP N/A
- PRPO N/A
- Fundamental
- Price
- OP $1.79
- PRPO $14.51
- Analyst Decision
- OP
- PRPO
- Analyst Count
- OP 0
- PRPO 0
- Target Price
- OP N/A
- PRPO N/A
- AVG Volume (30 Days)
- OP 6.0M
- PRPO 20.0K
- Earning Date
- OP 08-06-2025
- PRPO 08-12-2025
- Dividend Yield
- OP N/A
- PRPO N/A
- EPS Growth
- OP N/A
- PRPO N/A
- EPS
- OP N/A
- PRPO N/A
- Revenue
- OP $25,702,000.00
- PRPO $20,029,000.00
- Revenue This Year
- OP N/A
- PRPO N/A
- Revenue Next Year
- OP N/A
- PRPO N/A
- P/E Ratio
- OP N/A
- PRPO N/A
- Revenue Growth
- OP 35.58
- PRPO 26.67
- 52 Week Low
- OP $0.63
- PRPO $3.90
- 52 Week High
- OP $3.17
- PRPO $16.89
- Technical
- Relative Strength Index (RSI)
- OP 55.28
- PRPO 63.53
- Support Level
- OP $1.49
- PRPO $13.83
- Resistance Level
- OP $2.50
- PRPO $15.47
- Average True Range (ATR)
- OP 0.26
- PRPO 1.18
- MACD
- OP -0.00
- PRPO -0.01
- Stochastic Oscillator
- OP 48.51
- PRPO 62.16
About OP OceanPal Inc.
OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary. The company includes Dry Bulk segment and Tanker segment. Majority of revenue is Dry Bulk segment.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.